Antibody developer Yumab partners with Japanese AI specialist Molcure
German antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Forbion raises more than €2bn for two new funds
/in News/by Thomas GabrielczykDutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Lundbeck to take over Longboard Pharma in US$2.6bn transaction
/in News/by Thomas GabrielczykLundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
Sphingotec licenses kidney function test
/in News/by Thomas GabrielczykGerman diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.
AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc
/in News/by Thomas GabrielczykAviadoBio Ltd has cashed in €30m upfront and €20m as an equity investment from Astellas Pharma Inc for signing a licence option agreement for its Phase I/II gene therapy programme AVR-01.
Vicore secures funding to accelerate drug development
/in News/by Thomas GabrielczykSwedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
€20m loan for pandemic preparedness
/in News/by Thomas GabrielczykFab’entech, a French biopharma company, has secured a loan worth €20m from the European Investment Bank (EIB) under the HERA Invest programme, aimed at bolstering Europe’s preparedness against biological threats.
Kurma closes new fund at €250m
/in News/by Thomas GabrielczykKurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.
Genentech takes over Regor’s RGT-419B for US$850m upfront
/in News/by Thomas GabrielczykGenentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ RGT-419B for US$850m.
Spima Therapeutics starts with global licence agreement
/in News/by Thomas GabrielczykSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001